SEATTLE, March 16, 2011 (GLOBE NEWSWIRE) -- The article (), written by respected business writer Gene Marcial, provides insights into recent progress of TapImmune Inc. (OTCBB:TPIV), its research and development collaborations and the status of the Company's product portfolio.
The article also discusses the current market cap and potential market cap of the Company and predicts the Company's stock reaching its prior highs of $1.50 once the clinical programs begin and the Company's story gets broader attention.
Gene G. Marcial was Business Week's "Inside Wall Street" columnist for 28 years until Dec. 2, 2009, when Bloomberg took over the magazine. He is also a former columnist at the Wall Street Journal, where he wrote the "Heard on the Street" column and the "Abreast of the Market" column for more than seven and a half years.
Marcial now writes the "Inside Wall Street" column for AOL's DailyFinance.com and continues to be one of the most influential stock columnists, closely watched by investors and corporate executives alike.
TapImmune's unique approach is designed to increase the efficacy of vaccines by enhancing antigen presentation through the use of the Transporter of Antigen Processing ('TAP'). Replacement of this transporter provides a significant immune response with the potential to treat a variety of cancers which lack normal amounts of TAP.
TapImmune's lead product candidate, AdhTAP, is designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The Company is currently planning the development of AdhTAP for the commencement of clinical manufacturing and toxicology studies. As a stand-alone cancer therapy or in combination with other drugs, AdhTAP could prove to be a key component of a more successful assault on cancer. TapImmune is currently progressing development of a vaccine to treat HER-2/neu positive breast cancer and we anticipate the start of Phase I clinical trials in the near future.
The Company is also developing a TAP-based prophylactic vaccine which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times. TapImmune is also collaborating on a next generation smallpox vaccine. As a vaccine, TapImmune's TAP technology could significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases.
The TapImmune Inc. logo is available at
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at . The Company assumes no obligation to update the forward-looking statements.
CONTACT: Glynn Wilson, Chairman & CEO Taplmmune Inc. (866) 359-7541 Investor Relations (800) 953-3350